Strong Q2 results featured double-digit EPS and EBIT growth, margin expansion, and robust cash flow, prompting an upgrade in full-year EPS guidance to 10%-15%. Growth was broad-based across Kabi, Helios, and MedTech, with biopharma and innovation-led platforms driving performance.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.